$1.97 Billion is the total value of Camber Capital Management LP's 29 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 44.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | ALLERGAN PLC | $191,170,000 | +13.6% | 1,000,000 | 0.0% | 9.73% | +9.9% | |
| MYL | Buy | MYLAN N V | $175,875,000 | +4.6% | 8,750,000 | +2.9% | 8.95% | +1.2% |
| BIIB | BIOGEN INC | $103,856,000 | +27.5% | 350,000 | 0.0% | 5.28% | +23.3% | |
| GILD | New | GILEAD SCIENCES INC | $97,470,000 | – | 1,500,000 | +100.0% | 4.96% | – |
| THC | Sell | TENET HEALTHCARE CORP | $95,075,000 | +36.4% | 2,500,000 | -20.6% | 4.84% | +32.0% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $94,631,000 | +13.7% | 875,000 | +2.9% | 4.82% | +10.0% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $92,237,000 | +47.3% | 663,000 | +2.0% | 4.69% | +42.6% |
| BKD | BROOKDALE SENIOR LIVING | $90,875,000 | -4.1% | 12,500,000 | 0.0% | 4.62% | -7.2% | |
| PRGO | PERRIGO CO PLC | $87,822,000 | -7.6% | 1,700,000 | 0.0% | 4.47% | -10.5% | |
| ALKS | Buy | ALKERMES PLC | $84,150,000 | +23.2% | 4,125,000 | +17.9% | 4.28% | +19.2% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $80,944,000 | +48.1% | 3,750,000 | +25.0% | 4.12% | +43.3% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $77,424,000 | +37.1% | 600,000 | -20.0% | 3.94% | +32.6% |
| DVA | Sell | DAVITA INC | $75,030,000 | -12.4% | 1,000,000 | -33.3% | 3.82% | -15.2% |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $71,730,000 | -3.6% | 500,000 | 0.0% | 3.65% | -6.7% | |
| THOR | Sell | SYNTHORX INC | $69,890,000 | +130.7% | 1,000,000 | -46.3% | 3.56% | +123.3% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $64,123,000 | +41.4% | 3,250,000 | -7.1% | 3.26% | +36.8% |
| HCA | Sell | HCA HEALTHCARE INC | $59,124,000 | -18.2% | 400,000 | -33.3% | 3.01% | -20.8% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $58,028,000 | – | 730,000 | +100.0% | 2.95% | – |
| AMAG | AMAG PHARMACEUTICALS INC | $53,426,000 | +5.4% | 4,390,000 | 0.0% | 2.72% | +2.0% | |
| ATRA | ATARA BIOTHERAPEUTICS INC | $48,587,000 | +16.6% | 2,950,000 | 0.0% | 2.47% | +12.9% | |
| VTR | New | VENTAS INC | $43,305,000 | – | 750,000 | +100.0% | 2.20% | – |
| MYL | Sell | MYLAN N Vcall | $32,160,000 | -45.8% | 1,600,000 | -46.7% | 1.64% | -47.5% |
| MYGN | MYRIAD GENETICS INC | $27,230,000 | -4.9% | 1,000,000 | 0.0% | 1.39% | -8.0% | |
| MD | New | MEDNAX INC | $21,954,000 | – | 790,000 | +100.0% | 1.12% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $19,600,000 | – | 2,000,000 | +100.0% | 1.00% | – |
| GLYC | GLYCOMIMETICS INC | $18,515,000 | +22.7% | 3,500,000 | 0.0% | 0.94% | +18.8% | |
| TBIO | TRANSLATE BIO INC | $12,210,000 | -17.9% | 1,500,000 | 0.0% | 0.62% | -20.6% | |
| AVRO | Buy | AVROBIO INC | $12,078,000 | +71.1% | 600,000 | +20.0% | 0.62% | +65.8% |
| STRO | SUTRO BIOPHARMA INC | $6,600,000 | +21.0% | 600,000 | 0.0% | 0.34% | +17.1% | |
| SGRY | Exit | SURGERY PARTNERS INC | $0 | – | -160,084 | -100.0% | -0.06% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -750,000 | -100.0% | -0.81% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -500,000 | -100.0% | -1.12% | – |
| CYCN | Exit | CYCLERION THERAPEUTICS INC | $0 | – | -2,227,052 | -100.0% | -1.42% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -400,000 | -100.0% | -1.68% | – |
| NVO | Exit | NOVO-NORDISK A Sadr | $0 | – | -700,000 | -100.0% | -1.90% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -1,500,000 | -100.0% | -1.96% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -500,000 | -100.0% | -1.99% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -1,500,000 | -100.0% | -4.00% | – |
| AGN | Exit | ALLERGAN PLCcall | $0 | – | -500,000 | -100.0% | -4.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.